- MACK Dashboard
- Financials
- Filings
-
Holdings
- Transcripts
- ETFs
- Insider
- Institutional
- Shorts
-
CORRESP Filing
Merrimack Pharmaceuticals (MACK) CORRESPCorrespondence with SEC
Filed: 26 Sep 19, 12:00am
+1 617 526 6000 (t)
+1 617 526 5000 (f)
wilmerhale.com
September 26, 2019
Via EDGAR Submission
United States Securities and Exchange Commission
Division of Corporation Finance
Office of Mergers and Acquisitions
100 F Street, N.E.
Washington, D.C. 20549
Attention: Nicholas P. Panos
Re: | Merrimack Pharmaceuticals, Inc. |
PRER14A preliminary proxy statement filing made on Schedule 14A |
Filed September 20, 2019 by Merrimack Pharmaceuticals, Inc. |
File No. 001-35409 |
Ladies and Gentlemen:
Pursuant to our discussion with the staff of the Securities and Exchange Commission on September 23, 2019, Merrimack Pharmaceuticals, Inc. (the “Company”) is filing a Definitive Proxy Statement on Schedule 14A (the “Proxy Statement”) with regard to the Company’s October 17, 2019 Annual Meeting of Stockholders (“Annual Meeting”). As discussed, the Company has revised the footnotes to the beneficial ownership table contained under the heading “Stock Ownership and Reporting—Security Ownership of Certain Beneficial Owners and Management” in the Proxy Statement to specify that Newtyn Management, LLC and certain of its affiliated entities and Western Standard, LLC and certain of its affiliated entities are members of a “group” for the purposes of Section 13(d)(3) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). In addition, in light of JFL Partners Fund LP’s withdrawal of its nominees for the Annual Meeting, we have revised the Proxy Statement to remove the disclosures required for an election subject to the provisions of Exchange Act Rule 14a-12.
If you have any further questions or comments, or if you require any additional information, please contact the undersigned by telephone at (202) 663-6743 or facsimile at (202) 663-6363. Thank you for your assistance.
Very truly yours, | ||
By: | /s/ Lillian Brown | |
Lillian Brown |
cc: | Gary L. Crocker, Merrimack Pharmaceuticals, Inc. |
Brian A. Johnson, Wilmer Cutler Pickering Hale and Dorr LLP |
Hal J. Leibowitz, Wilmer Cutler Pickering Hale and Dorr LLP |
Wilmer Cutler Pickering Hale and DorrLLP, 60 State Street, Boston, Massachusetts 02109
Beijing Berlin Boston Brussels Denver Frankfurt London Los Angeles New York Oxford Palo Alto Washington